Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T19:13:25.446Z.
Calculation as of: 2026-10-06T19:13:25.446Z.
Quote observation: 2026-10-06T19:10:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 24a0b8a5defa6360a8df5348432e42fec2fdf5a1d44ff9a0d63a76d612d48360
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$1.10B
EV/Sales Ratio
2.92x
TTM Avg
4.22x
3Y Avg
4.31x
5Y Avg
7.99x
Market Cap
$1.11B
EV/Sales Ratio
1.71x
TTM Avg
1.73x
3Y Avg
2.34x
5Y Avg
3.98x
Market Cap
$1.11B
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.09B
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.08B
EV/Sales Ratio
11.87x
TTM Avg
13.52x
3Y Avg
10.24x
5Y Avg
9.95x
Market Cap
$1.14B
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.14B
EV/Sales Ratio
2.19x
TTM Avg
2.15x
3Y Avg
3.23x
5Y Avg
3.44x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Replimune Group, Inc. (REPL) | $1.10B | N/A | N/A | N/A | N/A |
| STAAR Surgical Company (STAA)vs › | $1.10B | 2.92x | 4.22x | 4.31x | 7.99x |
| Tandem Diabetes Care, Inc. (TNDM)vs › | $1.11B | 1.71x | 1.73x | 2.34x | 3.98x |
| First Tracks Biotherapeutics Inc (TRAX)vs › | $1.11B | N/A | N/A | N/A | N/A |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | N/A | N/A | N/A | N/A |
| OPKO Health, Inc. (OPK)vs › | $1.10B | 2.02x | 1.76x | 1.62x | 1.49x |
| IRadimed Corporation (IRMD)vs › | $1.08B | 11.87x | 13.52x | 10.24x | 9.95x |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.14B | N/A | N/A | N/A | N/A |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.14B | 2.19x | 2.15x | 3.23x | 3.44x |
| Harrow Health, Inc. (HROW)vs › | $1.14B | 4.91x | 6.64x | 6.66x | 5.94x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
